PneumaCare® announce the launch of their COPD Clinical Study

PneumaCare® Ltd are excited to announce the launch of their COPD (COPD Chronic Obstructive Pulmonary Disease) clinical study.  The study is a nationwide, comparative, multi-centered study designed to validate PneumaCare’s unique patented SLP based technology (Structured Light Plethysmography) against the current gold standard of care – spirometry.

The company’s mission is to provide a zero-contact, non-aerosol generating technology to actively assess lung function and to create diagnostic pathways in order to establish an enhanced standard of care. This pivotal study will focus on two objectives:

  • Firstly, to determine SLP parameters in patients diagnosed with COPD and compare them with the results from the SLP normative values and the data collated from healthy smokers.
  • Secondly, to validate SLP parameters for diagnosing patients diagnosed or suspected with COPD in comparison with spirometry results.

In the first stage of the study, PneumaCare will develop algorithms and parameters to predict FEV1 (the maximum amount of air forcefully exhaled in one second) and the final set of parameters will be validated in the second stage.

PneumaCare’s CEO Bart Lewin states,” If favorable results are achieved from the planned study, we envisage this will be an exciting time for the company, as it will further demonstrate that our SLP technology can be fully integrated into the UK’s health care system.

PneumaCare’s ambitious plan through this study is to establish an SLP based new standard of care to assist clinicians in the diagnosis of COPD. Specifically, to provide optimal algorithms to support a clear pathway to diagnosis.”

The first part of the study was initiated in May 2021, in Liverpool, one of the 6 investigational sites nationwide.  A total of 500 subjects will be enrolled over the two-stage study.  The study is expected to complete at the end of 2022.  Please visit ClinicalTrial.GOV website for more information.


Breaking new ground, PneumaCare® Ltd are at the forefront in changing the face of assessment in the respiratory field advancing non-contact, non-aerosol generating tidal breathing assessments. Using Thora-3Di®, patients can be assessed while breathing naturally and without contact.

Thora-3Di® and PneumaView™ are already being used in a range of hospital environments from paediatric through to surgical assessment and adult intensive care.  Further applications of PneumaCare’s proprietary Structured Light Plethysmography technology, currently in development with academics and clinicians, include dysfunctional breathing & COVID-19, pre & post-surgery applications.

For further information about the company and how our technology could support your organisation please visit or contact us